Healthcare >> Analyst Interviews >> December 5, 2001

Pharmaceutical Industry Overview: Jeffrey Kraws -grunatl & Co Llc

JEFFREY KRAWS is the Pharmaceutical Analyst and Senior Managing Director of the Healthcare Research Group at Gruntal & Co., LLC. Mr. Kraws was recently promoted to Director of Research for Gruntal & Co., LLC. Prior to Gruntal & Co., LLC, Mr. Kraws was the Managing Director of the Healthcare Research Group and the senior pharmaceutical analyst at First Union/Everen Securities. Mr. Kraws provides research coverage on large cap pharmaceutical, drug delivery, specialty pharmaceutical, biopharmaceutical, and medical technology companies. Prior to First Union/Everen Securities, Mr. Kraws was the Senior US Pharmaceutical Analyst for the global Swedish/Swiss conglomerate Asea Brown Boveri, as well as Managing Director and President of their US Brokerage/Investment Banking operation, ABB Aros Securities, Inc. He has over 10 years of overall experience and has previously been the Senior Pharmaceutical Analyst at Nationsbanc Montgomery Securities, BT Alex. Brown, Inc., and Buckingham Research. Mr. Kraws has been ranked numerous times as one of the top 20 Pharmaceutical Analysts in the industry by Institutional Investor, most recently in 1998, and was ranked among the top 10 Pharmaceutical Analysts in the industry for stock performance in 2000 as tabulated by analyst ranking from Mr. Kraws has also worked within the pharmaceutical industry, responsible for competitive analysis within the Treasury Group at Bristol-Myers Squibb. He holds an MBA from Cornell University and a Bachelor of Science from the State University of New York - Buffalo. Profile
TWST: What is the healthcare coverage at Gruntal?

Mr. Kraws: I'm a senior Pharmaceutical Analyst at Gruntal. I'm

responsible for the healthcare research team, as well as being the

Director of